Abstract
Purpose
Amuvatinib is a multi-targeted tyrosine kinase inhibitor with activity that also disrupts DNA damage repair through suppression of homologous recombination protein Rad51. Amuvatinib dry-powder capsules (DPC) showed evidence of activity in early Phase 1 cancer studies but low systemic exposure. The purposes of the studies were to investigate the cause of low exposure, develop, and test an alternative formulation with improved exposure, and establish the dose to be tested in future studies in cancer patients.
Methods
Three studies were conducted in a total of 58 healthy subjects: a food-effect study using amuvatinib DPC, a single-dose pharmacokinetic study comparing amuvatinib DPC to a new lipid-suspension capsules (LSC), and a multiple-dose pharmacokinetic study using amuvatinib LSC.
Results
A high-fat meal administered with amuvatinib DPC increased the rate and extent of absorption compared to the Fasted state, a 183 and 118% increase in the mean C max and AUC0–∞ of amuvatinib, respectively. The single-dose pharmacokinetics of amuvatinib LSC resulted in an approximately two-third-fold increased exposure (AUC) compared with amuvatinib DPC. The multiple-dose pharmacokinetics of the amuvatinib LSC 300 mg administered every 8 h exhibited improved accumulation compared with the 12-h regimens and achieved presumed therapeutic level safely with no serious or severe adverse events reported. No subject discontinued treatment due to an adverse event.
Conclusion
Amuvatinib LSC, 300 mg every 8 h, is being studied in cancer patients based on the improved exposure and similar safety profile to amuvatinib DPC. A lipid-based formulation approach may be a useful tool for other low aqueous soluble compounds.
This is a preview of subscription content, log in via an institution to check access.
References
Qi W, Cooke LS, Stejskal A, Riley C, Della Croce K, Saldanha JW, Bearss D, Mahadevan D (2009) MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 9:142. doi:10.1186/1471-2407-9-142
Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D (2007) A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26:3909–3919. doi:10.1038/sj.onc.1210173
Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B (2009) The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4:69. doi:10.1186/1748-717X-4-69
Zhao H, Luoto KR, Meng AX, Bristow RG (2011) The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. doi:10.1016/j.radonc.2011.08.013 (Epub ahead of print)
Taverna P, Huang L, Choy G, Azab M (2010) Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts. In: 2010 EORTC-NCI-AACR proceedings Abstract 171
Morgan SS, Wang ZJ, Taverna P, Cranmer LD (2010) Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines. In: 2010 EORTC-NCI-AACR proceedings Abstract 193
Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, Stuerzbecher HW (2005) High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93(1):137–143. doi:10.1038/sj.bjc.6602665
Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T (2003) The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 105(4):472–479. doi:10.1002/ijc.11106
Henning W, Sturzbecher HW (2003) Homologous recombination and cell cycle checkpoints: Rad51 in tumor progression and therapy resistance. Toxicology 193(1–2):91–109. doi:10.1016/S0300-483X(03)00291-9
Tolcher AW, Choy G, Joshi R, Redkar S, Fine G, Tibes R (2010) MP-470, a dual inhibitor of mutant kinases (c-KIT and PDGFRa) and DNA repair protein Rad 51—final results from a first-in-man single agent study. In: 2010 AACR proceedings Abstract 2749
Sankhala KK, Tolcher AW, Mita MM, Gordon MS, Rosen LS, Papadopoulos KP, Patnaik A, Drengler RL, Mita AC, Sarantopoulos J, Bristow R, Fine G, Choy GS, Azab M (2011) Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm Phase 1b trial in combination with 5 Standard of Care (SOC) anticancer regimens. In: 2011 ASCO proceedings Abstract 3074
Scholes PD, McDermott J, Vertommen J, Colin J-L, Choy G, Azab M, Joshi R, Redkar S (2010) Addressing the challenges of poor solubility: rapid development and clinical evaluation of a lipid based formulation to enhance oral bioavailability of amuvatinib (MP-470). In: 2010 AAPS proceedings Abstract R6077
Kissling CJ, Fine GD, Choy GS, Eddy C, Berk GI (2008) Effects of food on the single-dose pharmacokinetics of oral MP-470 capsules. Eur J Cancer 6(12):134 (suppl; abstr 426). doi:10.1016/S1359-6349(08)72360-7
Joshi R, Tang C, Inloes R, Shi C, Geddes D, Collier J, Rodriguez S, Mittan A, McLaughlin H, Fine G, Redkar S, Choy G (2009) A self-emulsifying lipid suspension formulation enhances oral bioavailability of MP-470 in a randomized two way crossover study in healthy male subjects. Mol Cancer Ther 8:12 (supp1; abstr B209). doi:10.1158/1535-7163.TARG-09-B209
Amidon GL, Lennernäs H, Shah VP, Crison J (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413–420. doi:10.1023/A:1016212804288
Porter CJ, Trevaskis NL, Charman WN (2007) Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6(3):231–248. doi:10.1038/nrd2197
Jain RK, Brar SS, Lesko LJ (2010) Food and oral antineoplastics: more than meets the eye. Clin Cancer Res 16:4305–4307. doi:10.1158/1078-0432.CCR-10-1857
Kang SP, Ratain MJ (2010) Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res 16:4446–4451. doi:10.1158/1078-0432.CCR-10-0663
Acknowledgments
The authors would like to acknowledge the contributions of Richard Mamelok, Sandra Calman, Joseph Iovino, Susana Flores, Debra Hathaway, and David Kashiwase. These studies were funded by Astex Pharmaceuticals, Inc. (formerly SuperGen, Inc.).
Conflict of interest
The studies were sponsored, monitored, and funded by Astex Pharmaceuticals, Inc. (formerly SuperGen, Inc.). Gavin Choy, Rajashree Joshi-Hangal, Aram Oganesian, Gil Fine, Amarpal Sahai, Mohammad Azab, and Sanjeev Redkar are employees of Astex Pharmaceuticals, Inc. Scott Rasmussen, Joanne Collier, and James Kissling declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choy, G., Joshi-Hangal, R., Oganesian, A. et al. Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers. Cancer Chemother Pharmacol 70, 183–190 (2012). https://doi.org/10.1007/s00280-012-1821-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-012-1821-2